Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

<p>Abstract</p> <p>Background</p> <p>Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties.</p> <p>Methods</p> <p>This ph...

Full description

Bibliographic Details
Main Authors: Anthony Stephen P, Stephenson Joe, Senzer Neil N, Cunningham C Casey, Eager Robert M, O'Day Steven J, Frenette Gary, Pavlick Anna C, Jones Barry, Uprichard Margaret, Nemunaitis John
Format: Article
Language:English
Published: BMC 2009-07-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/9/263

Internet

http://www.biomedcentral.com/1471-2407/9/263

Similar Items